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ARTICLE
TIGIT limits immune pathology during viral
infections
Michelle Schorer1, Nikolas Rakebrandt1, Katharina Lambert 1, Annika Hunziker2, Katharina Pallmer3,
Annette Oxenius 3, Anja Kipar 4, Silke Stertz2 & Nicole Joller 1✉
Co-inhibitory pathways have a fundamental function in regulating T cell responses and
control the balance between promoting efﬁcient effector functions and restricting immune
pathology. The TIGIT pathway has been implicated in promoting T cell dysfunction in chronic
viral infection. Importantly, TIGIT signaling is functionally linked to IL-10 expression, which
has an effect on both virus control and maintenance of tissue homeostasis. However, whether
TIGIT has a function in viral persistence or limiting tissue pathology is unclear. Here we
report that TIGIT modulation effectively alters the phenotype and cytokine proﬁle of T cells
during inﬂuenza and chronic LCMV infection, but does not affect virus control in vivo.
Instead, TIGIT has an important effect in limiting immune pathology in peripheral organs by
inducing IL-10. Our data therefore identify a function of TIGIT in limiting immune pathology
that is independent of viral clearance.
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Chronic viral infections represent a major burden onhuman health, and their effective treatment remains anunsolved challenge. One of the most striking features of
such chronic diseases is that effector T cells enter a state of
dysfunction also referred to as T cell exhaustion1,2. T cell
exhaustion is characterized by the gradual loss of T cell effector
functions as a consequence of continuous and prolonged antigen
exposure3,4. Exhausted T cells display highly upregulated and
sustained expression levels of co-inhibitory receptors, such as
PD-1, Lag-3, and Tim-3, fail to proliferate and show a defective
pro-inﬂammatory cytokine response5. Moreover, immune-
modulatory cytokines like IL-10 also play an important role in
disease progression during chronic infection, as it has been shown
that polymorphisms in IL-10 or IL10RA are associated with
increased susceptibility to chronic HCV and HBV infection6,7.
Importantly, many of these characteristics are shared by dys-
functional T cells that arise during the development of cancer,
and targeting co-inhibitory receptors has emerged as a potent
immune-modulatory strategy in order to “revitalize” the anti-
tumor response for the treatment of such conditions.
TIGIT (T cell immunoglobulin and ITIM domain) is a co-
inhibitory receptor that acts as an important immune checkpoint,
as it limits both T cell-driven inﬂammation and T cell and NK
cell-dependent anti-tumor immunity8,9. TIGIT is expressed on
activated T cells, regulatory T cells, and NK cells and binds two
ligands CD155 (PVR) and CD112 (PVRL2 or Necl5), that are
expressed on antigen-presenting cells (APCs)10,11 and tumor
cells12,13. CD226, the co-activating counterpart, competes with
TIGIT for the same ligands14, a feature which is reminiscent of
the CTLA-4/CD28 pathway. TIGIT is known to exert its immune
suppressive function through various modes of action, including
direct and indirect inhibition of T cells. It was shown that T cell
intrinsic TIGIT signaling directly inhibits T cell activation and
proliferation by attenuating TCR signaling9. Moreover, it was
demonstrated that TIGIT expression protects cells from NK-
mediated killing10, which highlights its role in promoting tumor
progression. Regulatory T (Treg) cells constitutively express high
levels of TIGIT at steady state11,15, which equips them with
superior suppressive capacity and indirectly suppresses effector
T cell responses16. In addition, TIGIT binding to its cognate
receptor CD155 on dendritic cells leads to the indirect suppres-
sion of T cell responses via induction of the immune suppressive
cytokine IL-10 in DCs11. Importantly, loss of TIGIT results in
hyperproliferative and inﬂammatory T cell responses and a
marked reduction in IL-109,14. IL-10 itself is a key regulator of
immune responses during infections, where it plays a two-sided
role by both promoting pathogen persistence17–19 as well as
limiting excessive Th1 and CD8+ T cell responses that cause
immune pathology20,21. Incidentally, many chronic or latent
human viruses have evolved to encode IL-10 homologs in order
to evade immune control22. Nevertheless, the resolution of
inﬂammatory processes relies on the tightly controlled balance
between pro-inﬂammatory and regulatory immune responses,
which is especially evident during the pathogenesis of neurotropic
protozoa such as Plasmodium falciparum, Trypanosoma cruzi, or
Toxoplasma gondii, where IL-10 signaling was demonstrated to
restrict cytokine-mediated immune pathology23,24. TIGIT
blockade or deﬁciency has been shown to lead to the breakdown
of peripheral tolerance in HBsAg-tg mice, resulting in the
development of hepatitis and ﬁbrosis25. At the same time, TIGIT
upregulation was shown to support tissue regeneration in vivo by
negatively regulating NK cell activation26. Thus, a better under-
standing of immune-modulatory receptors and their impact on
both pathogen control as well as maintaining tissue protection is
crucial, especially in the view of their increased use as checkpoint
inhibitors in the clinics.
As TIGIT ligation is functionally linked to IL-10 expression
that is known to both promote virus persistence in vivo, but also
limit adverse immunopathological damage, the TIGIT pathway
might represent an important regulatory gatekeeper for the
control of viral infections. Therefore, we investigated the role of
TIGIT in modulating T-cell responses following chronic LCMV
infection as well as its contribution to restricting immune
pathology. Here, we report that TIGIT modulation effectively
alters the cytokine proﬁle and IL-10 expression levels in vivo.
However, TIGIT blockade or stimulation alone is not sufﬁcient to
promote virus clearance or persistence but rather plays an
important role in limiting immune pathology in peripheral
organs in an IL-10-dependent manner.
Results
TIGIT is upregulated during chronic LCMV infection. In a ﬁrst
line of investigation, we sought to identify whether TIGIT is
expressed on exhausted T cells upon chronic viral infection with
LCMV clone 13, the classical model to study T cell exhaustion
and viral persistence4,5. We found that TIGIT is indeed highly
expressed during the course of chronic LCMV clone 13 infection
on both CD4+ and CD8+ T cells as well as on Tregs (Fig. 1a–c,
h), the latter displaying the highest expression of TIGIT
throughout the course of infection. TIGIT expression was parti-
cularly high on exhausted PD-1+ Tim-3+ CD8+ T cells (Fig. 1f),
but not on PD-1− Tim-3− CD8+ T cells. We next asked whether
TIGIT was also upregulated on antigen-speciﬁc T cells that are
known to become exhausted during chronic viral infections. In
order to follow antigen-speciﬁc T cells, Ly5.1+ TCR transgenic
CD8+ and CD4+ T cells speciﬁc for the immuno-dominant gp33
(P14) or gp61 (Smarta) peptides were transferred into wild-type
(WT) C57BL/6 mice prior to LCMV clone 13 infection. Indeed,
antigen-speciﬁc T cells expressed high levels of TIGIT during the
chronic phase of the infection starting from day 20 p.i. (Fig. 1d,
e), suggesting that like PD-127,28, TIGIT expression is maintained
in response to continuous TCR stimulation. Given that T cell-
derived IL-10 was shown to contribute to T cell suppression and
viral persistence in the LCMV model18,29, we next tested whether
TIGIT expression correlates with IL-10 production in vivo. We
used Thy1.1-IL-10 reporter mice that carry a bacterial artiﬁcial
chromosome Il-10 promotor transgene with a Thy1.1 cDNA
insertion in order to reliably identify IL-10-producing cells30. In
line with TIGIT being expressed on exhausted cells, TIGIT+
CD8+ T cells displayed signiﬁcantly higher levels of IL-10 on day
30 p.i. than TIGIT− CD8+ T cells (Fig. 1g). Taken together, these
ﬁndings suggest that TIGIT marks a PD-1+ IL-10-producing
exhausted CD8+ T-cell population that arises during chronic
LCMV infection.
TIGIT modulates co-inhibitory receptors on CD8+ T cells. In
order to determine the functional contribution of the TIGIT
pathway toward promoting T cell exhaustion during chronic
LCMV infection, we targeted TIGIT in vivo by using the blocking
anti-TIGIT antibody (clone 1B4) we have generated and char-
acterized previously31. Chronically infected C57BL/6 mice were
continuously treated with either anti-TIGIT or mouse IgG1
control antibodies starting on the day of infection. We observed
that TIGIT blockade signiﬁcantly altered the exhaustion pheno-
type of CD8+ T cells. During the chronic phase of the infection
(day 30 p.i.), CD8+ T cells from anti-TIGIT-treated mice dis-
played markedly lower PD-1 and Tim-3 expression levels than
controls (Fig. 2a, c). Decreased expression of PD-1, and Tim-3 on
CD8+ T cells, was also detectable during early phases of LCMV
clone 13 infection and remained considerably reduced until day
40 p.i. (Supplementary Fig. 1A). PD-1 expression was also
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signiﬁcantly decreased on CD4+ T cells, however, only during
early stages of infection (Supplementary Fig. 1B), while the PD-1
expression on regulatory T cells remained unchanged over the
course of chronic infection. The in vivo anti-TIGIT antibody
(clone 1B4) was already shown to be non-depleting after
immunization with MOG peptide31 and we conﬁrmed these
ﬁndings in chronic LCMV infection (Supplementary Fig. 1C).
Because lack of TIGIT signaling could also have a negative impact
on myeloid cells that express the ligand, we quantiﬁed the
abundance of various populations of antigen-presenting cells in
the spleen (Supplementary Fig. 1D, E), but could not detect any
noticeable differences, neither regarding their frequency nor their
absolute numbers. Moreover, we analyzed the NK cell phenotype
over the course of acute and chronic LCMV infection with and
without anti-TIGIT Ab administration and found them to be
comparable (Supplementary Fig. 2A–E).
In order to determine whether TIGIT might be able to actively
promote T-cell exhaustion, we infected WT mice with an
intermediate dose of LCMV clone 13 (1 × 105 FFU), which
results in an acute infection that is cleared within 10 days and
treated them with either an agonistic anti-TIGIT antibody (1G9)
or IgG1 isotype control. Indeed, antibody-mediated TIGIT
engagement resulted in increased PD-1 and Tim-3 expression
on CD8+ T cells on day 14 p.i. (Fig. 2b, d). These results
demonstrate that TIGIT modulation has an impact on the
exhaustion phenotype of T cells.
TIGIT correlates with IL-10 production in vivo. Given that IL-
10 was shown to contribute to viral persistence in vivo19,29,32 and
that TIGIT signaling induces the production of IL-10 both
directly and indirectly11,31, we speculated that TIGIT might hold
a central role in contributing to viral persistence through its
ability to induce IL-10. To further investigate this link between
TIGIT and IL-10 expression in vivo, we chronically infected
Thy1.1-IL-10 reporter with LCMV clone 13 and again treated
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Fig. 1 TIGIT expression during chronic LCMV clone 13 infection. TIGIT expression on splenic T cells was analyzed after chronic LCMV clone 13 infection
(2 × 106 FFU) using ﬂow cytometry. Expression over time on (a) CD8+ T cells, (n= 2–16), (b) CD4+ T cells (n= 2–17), and (c) CD4+FoxP3+ regulatory
T cells (n= 2–13) is shown. TIGIT expression on (d) P14 Ly5.1+ TCR transgenic CD8+ T cells speciﬁc for gp33, (n= 4–6) and (e) Smarta CD4+ T cells
speciﬁc for gp61 (n= 4–7). f TIGIT expression on exhausted (PD1+Tim-3+) or non-exhausted (PD1−Tim-3−) CD8+ T cells on day 30 p.i. (n= 10). g IL-10-
Thy1.1 expression in Thy1.1-IL-10 reporter mice by TIGIT+ and TIGIT- CD8+ T cells on day 30 p.i. (n= 10). h Representative FACS plots of TIGIT expression
on T cells on day 30 p.i. with chronic LCMV clone 13. Data represent 2–3 independent experiments. Each symbol in the scatter plot represents an individual
mouse, and bar graphs indicate the mean value ± SD. Statistical values p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) or ns (not signiﬁcant, p > 0.05)
determined by Welch’s t test.
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them with blocking anti-TIGIT antibody (1B4) or isotype control.
TIGIT blockade resulted in a decrease in the frequency of IL-10-
Thy1.1+ CD8+ T cells (Fig. 3a). Vice versa, TIGIT engagement in
the course of acute LCMV infection using the agonistic anti-
TIGIT antibody led to signiﬁcantly increased frequencies of both
IL-10-Thy1.1+ CD8+ T cells and IL-10-Thy1.1+ CD4+ T cells
(Fig. 3a). Yet, TIGIT modulation did not affect overall numbers of
IL-10-Thy1.1+ T cells in the spleen in any of the infection models
(Fig. 3b). Nevertheless, evaluation of serum IL-10 levels in
chronically infected mice revealed an early drop of IL-10 around
day 14 p.i. in mice treated with blocking anti-TIGIT antibody
(1B4) (Fig. 3c). To conﬁrm these observations, we analyzed
supernatants of anti-CD3 in vitro re-stimulated splenocytes from
chronically infected mice (day 30 p.i.). In line with our previous
ﬁndings, TIGIT blockade correlated with signiﬁcantly decreased
levels of IL-10 (Fig. 3d). In turn, engagement of the TIGIT
pathway in acutely infected mice resulted in elevated serum levels
of IL-10 (Fig. 3e). Within the T cell compartment, only effector
T cells displayed an altered IL-10 phenotype. In addition, we
analyzed the Thy1.1 expression in myeloid cell populations
during both acute and chronic LCMV infection. During early
acute LCMV infection, we could not detect any signiﬁcant dif-
ferences regarding the frequency of IL-10-Thy1.1+ cells between
control and agonistic anti-TIGIT (1G9) antibody-treated mice
(Supplementary Fig. 3A). On day 14 p.i., CD11b+Ly6C+ cells
showed signiﬁcantly higher expression of IL-10-Thy1.1 after
treatment with the agonistic anti-TIGIT (1G9) Ab (Supplemen-
tary Fig. 3B), which mimics the ﬁndings observed in the T cell
compartment. However, the overall frequency of IL-10-Thy1.1+
cells was much smaller than in the T cell compartment. Similarly,
we did not observe any differences in IL-10-Thy1.1 expression
during the early phase of chronic LCMV infection on myeloid
cells (Supplementary Fig. 3C), but found a trend toward
decreased expression of IL-10-Thy1.1 in CD11b+Ly6G+ cells
during the chronic stage of the infection (Supplementary Fig. 3D),
however, this did not reach signiﬁcance. Collectively, these data
reveal a functional link between TIGIT engagement and IL-10
induction during LCMV infection.
TIGIT dampens pro-inﬂammatory cytokines in acute infec-
tion. A cardinal feature of exhausted T cells is the hierarchical
and progressive loss of pro-inﬂammatory cytokine production,
where IL-2 secretion is abolished prior to TNF secretion, and
T cell exhaustion ﬁnally becomes terminal when the ability to
produce IFN-γ is lost2,33. Conversely, we and others have pre-
viously shown that agonistic anti-TIGIT antibodies reduce pro-
inﬂammatory cytokine production, both in vitro and
in vivo9,14,31. We thus next analyzed whether TIGIT can mod-
ulate the expression of pro-inﬂammatory cytokines in T cells
during both acute and chronic LCMV infection.
Agonistic anti-TIGIT antibody (1G9) treatment in acutely
LCMV infected mice resulted in markedly reduced production of
IFN-γ, but not TNF-α in CD8+ T cells (Fig. 4a–c). Similarly,
CD4+ T cells also produced signiﬁcantly lower amounts of IFN-γ
after anti-CD3 re-stimulation (data not shown). Furthermore,
agonistic anti-TIGIT antibody (1G9) administration resulted in
the pronounced inhibition of T cell function on day 5 p.i. as
indicated by the decreased expression of activation markers and
pro-inﬂammatory cytokine production measured by FACS,
conﬁrming its immune suppressive properties (Supplementary
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Fig. 2 In vivo TIGIT modulation alters co-inhibitory receptor expression on T cells after LCMV infection. C57BL/6 mice were infected with either 2 × 106
FFU LCMV clone 13 i.v. (red, chronic) or 1 × 105 FFU LCMV clone 13 i.v. (gray, acute) and treated with 100 μg of blocking anti-TIGIT Ab (1B4, chronic
infection), agonistic anti-TIGIT Ab (1G9, acute infection), or mouse IgG1 i.p. Representative FACS plots (a, b) and summary data (c, d) of co-inhibitory
receptor expression on splenic CD8+ T cells after (a, c) chronic LCMV infection (day 30, n= 10-25), and (b, d) acute LCMV infection (day 14, n= 11–22)
are shown. Data represent pooled data from four to ﬁve independent experiments. Each symbol in the scatter plot represents an individual mouse, and bar
graphs indicate the mean value ± SD. Statistical values p < 0.05 (*), p < 0.01 (**), p < 0.005 (***), or ns (not signiﬁcant, p > 0.05) determined by Welch’s
t test.
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Fig. 4A–D). In line with these results, TIGIT blockade yielded a
modest but signiﬁcant increase of TNF-α expression by CD8+
T cells after re-stimulation with anti-CD3 (Fig. 4d, e). However,
there was no difference in IFN-γ levels or in IL-2 production,
which was below the detection limit (data not shown).
Unexpectedly, CD8+ T cells from control or anti-TIGIT antibody
(1B4) treated chronically infected mice displayed no differences
regarding TNF-α and IFN-γ production when re-stimulated in an
antigen-speciﬁc manner (Fig. 4f). Taken together, these results
demonstrate that TIGIT blockade during chronic LCMV
infection only exerts a modest effect on pro-inﬂammatory
cytokine production by T cells, whereas TIGIT stimulation
during acute infection effectively inhibits the production of IFN-γ
by both effector T cell subsets.
Loss of virus-speciﬁc T cells upon TIGIT blockade. Since virus-
speciﬁc CD8+ T cells play a critical role in virus clearance and
were demonstrated to be most severely affected by exhaustion and
deletion following high dose LCMV infection34, we undertook
further experiments to investigate the LCMV-speciﬁc T cell
response. To this end, we adoptively transferred Ly5.1+ TCR
transgenic CD8+ P14 cells into Ly5.2 recipient mice one day prior
to chronic LCMV clone 13 infection. Strikingly, TIGIT blockade
severely reduced the number of virus-speciﬁc P14 cells in the
blood of chronically infected mice (Fig. 5a). The same pattern was
observed when endogenous CD8+ T cells were stained with the
gp33 peptide/MHCI tetramer against gp33 (Fig. 5b). Con-
currently, the number of IFN-γ-producing P14 cells was sig-
niﬁcantly reduced early during chronic infection (Fig. 5c), but
evened out by day 20 p.i. Furthermore, in contrast to total CD8+
T cells the transferred P14 cells displayed elevated co-inhibitory
receptor expression after TIGIT blockade (Fig. 5d), as well as
slightly reduced pro-inﬂammatory cytokine production on day 30
after chronic LCMV challenge (Fig. 5e, f), indicative of a more
exhausted phenotype. A population of TCF-1+ CD8+ T cells was
previously shown to be critical to sustain the anti-viral immune
response during chronic LCMV infection, as this subset serves as
the source of cells that gives rise to differentiated effector like cells
that respond to checkpoint blockade in vivo35. Interestingly, we
found that TIGIT blockade leads to the loss of these TCF-1+ CD8+
T cells in both transferred antigen-speciﬁc and endogenous CD8+
T cells (Supplementary Fig. 5A, B).
Given that the virus-speciﬁc cells seemed to be impaired
following TIGIT blockade, but total T cells showed enhanced
TNF-α production, we next addressed how inhibition of the TIGIT
pathway would affect viral loads and persistence. We observed that
TIGIT blockade failed to promote virus clearance in the spleen and
kidneys of chronically infected animals (Fig. 5g, h). Similarly, we
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(gray) are depicted (n= 7–13). IL-10 protein levels were measured by cytometric bead assay in (c) the serum of chronically (d30 p.i.) infected mice (n=
1–6 sera pooled from three mice) and (d) supernatants of ex vivo cultured splenocytes isolated on day 30 p.i. after chronic LCMV clone 13 infection re-
stimulated with anti-CD3 (n= 3, pooled from nine mice) and (e) supernatants of ex vivo cultured splenocytes isolated on day 14 after acute LCMV clone 13
infection re-stimulated with anti-CD3 (n= 4). Pooled data from two to three independent experiments are shown. Each symbol in the scatter plot
represents an individual mouse or pooled data point and bar graphs indicate the mean value ± SD. Statistical values p < 0.05 (*), p < 0.01 (**), p < 0.005
(***), or ns (not signiﬁcant, p > 0.05) were determined by Welch’s t test.
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found that TIGIT stimulation during acute viral infection only
temporarily impacts viral titers, as the virus was generally cleared
by day 14 p.i. despite elevated virus loads in the spleen, but not the
liver at an early time point (day 5 p.i.; Supplementary Fig. 4E–G).
Collectively, these data suggest that TIGIT modulation alone is
insufﬁcient to affect viral persistence in vivo.
TIGIT limits tissue damage in an IL-10-dependent manner.
Despite the fact that TIGIT modulation did not affect viral loads
following acute LCMV infection by day 14 p.i., we noticed
marked differences regarding body weight loss between IgG1 and
agonistic anti-TIGIT antibody (1G9) treated mice (Fig. 6a).
Control mice showed a slight drop of around 8% of their initial
body weight early during acute LCMV infection, which was not
observed in agonistic anti-TIGIT antibody (1G9)-treated mice,
the latter of which maintained or even gained weight over the
course of infection. Because TIGIT engagement allows for the
effective modulation of IL-10, which in turn plays an important
role in the resolution of inﬂammation in various infectious as well
as autoimmune models36–38, we hypothesized that TIGIT-
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Fig. 4 TIGIT ligation results in decreased pro-inﬂammatory cytokine production after acute infection. C57BL/6 mice were infected with either 2 × 106
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mediated induction of IL-10 could protect against immune
pathology. LCMV infection is known to cause T cell-dependent
liver damage39. We thus sought to test if TIGIT stimulation might
limit tissue damage by inhibiting T cell activation and inﬁltration
in the liver. In order to characterize and quantify the immune
pathological changes, we measured serum levels of aspartate
aminotransferase (AST) and alanine transaminase (ALT), which
are indicative of injured or damaged hepatocytes40. In line with
our hypothesis, we found that TIGIT engagement resulted in
signiﬁcantly decreased AST and ALT levels on day 14 p.i. (Fig. 6b,
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a The body weight of acutely infected mice over the course of infection with or without anti-TIGIT Ab (1G9) treatment is shown (n= 10). Serum levels of
AST (b) and ALT (c) quantiﬁed by enzymatic activity assay on day 14 p.i. fromWT, IL-10 KO, and PKOB mice are shown (n= 5–8). d–f Tissue damage was
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c). In order to better understand the effect of agonistic anti-TIGIT
antibody (1G9) treatment, we undertook a histological exam-
ination of the livers of animals sacriﬁced on day 14 p.i. H&E
staining of the livers revealed a similar pattern of disease in both
experimental groups. We could observe on-going parenchymal
damage, illustrated by the presence of scattered dying hepatocytes
and evidence of active leukocyte recruitment and inﬁltration. The
latter was indicated by the presence of leukocytes in the lumen of
central veins and their rolling along endothelial cells. Leukocytes
often appeared activated, with leukocyte inﬁltration stretching
from central veins to hepatic cords (Fig. 6f). Leukocyte inﬁltration
was also seen in portal areas and as random aggregates in the
parenchyma. However, the magnitude of histopathological
changes and overall disease score was signiﬁcantly decreased in
mice receiving agonistic anti-TIGIT antibody (1G9) treatment,
especially regarding portal vein inﬂammation and central vein
inﬁltration (Fig. 6d–f). Collectively, these ﬁndings link TIGIT to
restricting immune-mediated liver damage during acute LCMV
infection.
We next tested whether IL-10 is involved in mediating the
reduced inﬂammatory response in agonistic anti-TIGIT treated
mice and repeated the acute LCMV infection in IL-10 KO mice.
In contrast to WT mice, agonistic anti-TIGIT treatment had no
effect on AST or ALT levels in IL-10 KO mice (Fig. 6b, c). Serum
AST and ALT levels in the IL-10 KO mice at this time point were
generally very low compared with WT animals due to accelerated
viral clearance and hence faster resolution of inﬂammation in IL-
10 KO mice (Supplementary Fig. 6A–C, F, G). However, analysis
of serum samples obtained on day 5 p.i. showed higher AST levels
in IL-10 KO in comparison with WT mice (Supplementary
Fig. 6D, E), which supports the notion that enzyme leakage from
the liver occurs as a consequence of IL-10 deﬁciency, albeit
following accelerated kinetics. In line with the results obtained on
day 14, the liver protective effect of agonistic anti-TIGIT
treatment was dependent on IL-10 as IL-10 KO mice showed
no difference in AST/ALT levels upon treatment on day 5 p.i.
(Supplementary Fig. 6D, E). An important mediator of tissue
damage is perforin, which was shown to contribute to CD8+
T cell-dependent hepatitis in a model of virally induced immune
pathology41 and to CD8+ T cell-driven immunopathology in PD-
L1-deﬁcient mice upon LCMV infection42. Therefore, we
speculated that TIGIT might be involved in regulating perforin-
dependent tissue damage following acute virus infection. In order
to test this, we infected PKOB mice with acute LCMV and either
treated with control IgG1 or agonistic anti-TIGIT antibody
(1G9). We found that the effect of TIGIT agonism is lost in
PKOB mice, which suggests that the pathological process
inhibited by TIGIT is perforin dependent (Fig. 6b, c).
To determine whether TIGIT stimulation results in local IL-10
production and an IL-10 dominated local immune environment,
we next analyzed the immune inﬁltrates in the liver after acute
LCMV challenge. Indeed, agonistic anti-TIGIT antibody (1G9)-
treated mice showed a markedly increased frequency of IL-10-
producing T cells in the liver (Fig. 6g). However, there was no
difference regarding the overall number of IL-10-producing
T cells (data not shown). Furthermore, no difference regarding
the frequency of IFN-γ+ CD8+ T cells in the liver could be
observed, irrespective of antigen-unspeciﬁc or -speciﬁc re-
stimulation (Fig. 6h). More importantly, the ratio of IL-10+ to
IFN-γ+ cells was strongly shifted toward an anti-inﬂammatory
cytokine proﬁle in the tissue in anti-TIGIT-treated groups
(Fig. 6i), supporting the notion that TIGIT favors the generation
of a regulated immune environment and limits immune-
mediated tissue damage in an IL-10-dependent manner. What
is more, we tested if blocking anti-TIGIT antibody (1B4)
administration has the potential to exacerbate disease severity.
TIGIT blockade resulted in delayed recovery from chronic LCMV
infection-induced body weight loss (Supplementary Fig. 7A).
However, this did not go along with increased enzyme leakage
from the liver (Supplementary Fig. 7B). Along the same lines,
TIGIT blockade did neither lead to increased tissue pathology in
any of the examined disease models, nor did it have an inﬂuence
on virus loads (Supplementary Fig. 7C–F).
To further explore whether the tissue-protective effect of
TIGIT was restricted to LCMV infection or whether it represents
a general feature of the TIGIT pathway, we tested the effect of the
agonistic anti-TIGIT antibody after inﬂuenza virus infection, a
highly cytopathic virus. Anti-TIGIT and control-treated WT and
IL-10 KO mice were infected with the mouse adapted H1N1
inﬂuenza A virus PR8, and the extent of tissue damage in the
lungs was determined on day 8 p.i. In line with our ﬁndings in
LCMV infection, TIGIT pathway engagement resulted in
signiﬁcantly decreased vascular leakage as indicated by the
reduced levels of albumin-bound Evan’s blue (EB) dye recovered
from the lungs of anti-TIGIT-treated mice (Fig. 7a). Importantly,
this effect was IL-10 mediated, as PR8 challenged IL-10 KO mice
showed a reversed phenotype after agonistic anti-TIGIT antibody
(1G9) treatment when compared with isotype controls (Fig. 7b).
Moreover, agonistic anti-TIGIT antibody treatment led to a
signiﬁcantly decreased frequency of IFN-γ producing CD8+
T cells in the lungs of infected animals (Fig. 7c). At the same
time, CD8+ and CD4+ T cells expressed markedly higher levels
of IL-10 compared with IgG1-treated controls (Fig. 7d). Further-
more, total numbers of IL-10-producing CD8+ T cells were
signiﬁcantly increased in the lungs after TIGIT stimulation
(Fig. 7e). Overall, the cytokine production in the lungs of anti-
TIGIT antibody-treated mice was skewed toward an IL-10-
dominated immune response, as the ratio of IL-10 to IFN-γ and
TNF-α-producing T cells was greater in these animals (Fig. 7f). In
addition, IL-10 protein levels were signiﬁcantly elevated in lung
homogenates of mice treated with agonistic anti-TIGIT antibody
(1G9) compared with IgG1 controls (Fig. 7g). Importantly, anti-
TIGIT treatment had no effect on inﬂuenza titers in both
bronchoalveolar lavage (BAL) and lungs of infected animals
throughout the course of PR8 infection (Supplementary Fig. 8A,
B). PR8 infection lead to moderate vasculitis, which was most
pronounced in IgG1-treated control mice. We also observed
stronger evidence of on-going leukocyte recruitment into the
tissue, which was most evident by the higher frequency and
intensity of vasculitis in the control group (Supplementary
Fig. 8C–E). Taken together, these ﬁndings further support the
notion that the differences in tissue damage during PR8 infection
were not a result of differential virus replication in the tissue, but
rather the consequence of TIGIT-dependent immune modula-
tion. In summary, these data reveal an important role of the
TIGIT pathway in limiting immune-mediated tissue damage
during acute virus infection in an IL-10-dependent manner.
Discussion
Co-inhibitory pathways serve as central, negative regulators of
immune cell functions, and have proven to be powerful targets for
therapeutic immune modulation in diverse disease indications.
The TIGIT inhibitory pathway is known to play an important
role in limiting autoimmunity as well as negatively regulating
anti-tumor responses. In this study, we investigated the sig-
niﬁcance of the TIGIT pathway in modulating T cell function
during viral infections. We determined the impact of TIGIT
blockade, as well as TIGIT engagement, on T cell function and
phenotype during chronic and acute LCMV infections, respec-
tively, and found that rather than promoting T cell dysfunction
and viral persistence like other co-inhibitory receptors, TIGIT
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plays a critical role in protecting against immune pathology
in vivo via induction of the immune-modulatory cytokine IL-10.
Chronic LCMV infection represents the prototypic model to
study T cell exhaustion, where simultaneous co-expression of
several inhibitory receptors marks T cells with diminished
effector function34,43. We found that antibody-mediated TIGIT
blockade during chronic LCMV infection resulted in marked
downregulation of other co-inhibitory receptors, such as PD-1,
Tim-3, and Lag-3 on total CD8+ T cells and on CD4+ T cells. In
contrast to CD8+ T cells, where co-inhibitory receptor expression
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of IFN-γ+ CD8+ and CD4+ T cells. d Frequency of IL-10-Thy1.1+ CD8+ and CD4+ T cells. e Absolute numbers of IL-10-Thy1.1+ CD8+ and CD4+ T cells
and (f) the ratio of total IFN-γ+ to IL-10+ CD8+ T cells and TNF-α+ to IL-10+ CD8+ T cells are displayed (n= 4–5). g IL-10 protein levels were measured in
whole-lung homogenates by cytometric bead assay (n= 9). Each symbol in the scatter plot represents an individual mouse and bar graphs indicate the
mean value ± SD. Statistical values p < 0.05 (*), p < 0.01 (**), p < 0.005 (***), ns (not signiﬁcant, p > 0.05) determined by Student’s t test (two
experimental groups) or one-way ANOVA (more than two experimental groups). Cytokine ratio data were evaluated using two-tailed Mann–Whitney test.
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was signiﬁcantly lower throughout the duration of the chronic
infection, PD-1 downregulation was only transient on CD4+
T cells and occurred during early stages of the infection. This
might contribute to CD8+ dysfunction, since CD4+ help has been
described to be essential for effective virus clearance in this
system44,45. TIGIT blockade also modestly increased the pro-
duction of TNF-α by CD8+ T cells. Consistent with our ﬁndings
after TIGIT blockade, antibody-mediated TIGIT stimulation
correlated with the concomitant induction of PD-1 on CD8+
T cells, which supports the notion that TIGIT at least partially
contributes to the development of T cell exhaustion. Moreover,
we found that early T cell activation was signiﬁcantly reduced
after agonistic TIGIT ligation in vivo, which correlated with the
considerably reduced production of pro-inﬂammatory cytokines.
This is in line with previous reports demonstrating the potential
of TIGIT to attenuate T cell responses9,15,31.
Moreover, we were able to establish that TIGIT ligation in vivo
results in enhanced induction of the immunosuppressive cytokine
IL-10 in response to acute LCMV challenge. Vice versa we could
verify that TIGIT blockade leads to the diminished expression of
IL-10 by CD8+ T cells during chronic infection, which indicates
that TIGIT is involved in shifting the cytokine balance toward a
more IL-10 dominated immune response in the context of viral
infections. Reports from different groups including our own
support this concept, as TIGIT expression was demonstrated to
correlate with IL-10 expression in a model of antigen-speciﬁc
tolerance46, as well as peptide immunization9,31. Notably, TIGIT
blockade alone was insufﬁcient to promote viral clearance in the
LCMV clone 13 model, which is consistent with previous reports
showing that only co-blockade of TIGIT and PD-L1 restores the
cytokine production of exhausted T cells and enhances viral
clearance8,47. Surprisingly, TIGIT blockade resulted in the loss of
antigen-speciﬁc T cells, which could account for the failure of the
anti-TIGIT treatment to promote viral clearance. One potential
mechanism that might contribute to lower cell counts could be
enhanced cell death as a consequence of hyperactivation of these
cells. Activation-induced cell death (AICD) occurs after repeated
stimulation of the TCR and is important for maintaining immune
homeostasis. AICD has also been described to be a major cause of
T cell depletion in other chronic infections, such as HIV48,49,
independent of direct cytotoxic effects of the virus itself. Intri-
guingly, Tim-3 and Lag-3 also appear to be dispensable for the
development of T cell exhaustion, as Tim-3 KO and Lag-3 KO
mice were demonstrated to harbor fewer antigen-speciﬁc T cells
and do not control virus replication after challenge with chronic
LCMV clone 1350,51. In contrast, PD-1/PD-L1 blockade during
chronic viral infections restores the function of exhausted CD8+
T cells, in particular antigen-speciﬁc cells, and results in enhanced
T cell responses and virus control in different virus models8,52,53,
which suggests that these two molecules operate through distinct
pathways to dampen immune cell responses and might thus
partake in different physiological processes, where immune sup-
pression is required.
Strikingly, lack of PD-1/PD-L1 signaling has been shown to
be associated with pronounced immune pathology and increased
mortality very early after systemic LCMV clone 13 infec-
tion42,52,54. Given that TIGIT−/− mice do not develop sponta-
neous signs of autoimmunity8,9, it is tempting to speculate that
TIGIT possesses a more localized role that is subordinate to PD-1.
LCMV is known to inﬂict severe liver pathology as a consequence
of virus-speciﬁc CD8+ T cell activation39,55, and remarkably, we
found that antibody-mediated TIGIT stimulation signiﬁcantly
reduced the secretion of liver-derived enzymes AST and ALT into
the blood. What is more, we conﬁrmed that TIGIT engagement
protected acutely infected mice from weight loss and restricted
leukocyte inﬁltration and inﬂammation in the liver. These
ﬁndings could also be validated in an inﬂuenza model. Whether
this also translates into improved survival in infections with lethal
doses of virus will have to be addressed in future studies. Our
study showed that engagement of the TIGIT pathway limited
infection-induced liver and lung damage in an IL-10-dependent
manner, thus revealing a critical mechanistic aspect of TIGIT
biology. The fact that the ameliorated liver pathology was
dependent on IL-10 is consistent with established knowledge
showing that IL-10 in particular is essential for negative immune
cell regulation56. The vital role of IL-10 in protecting against
immune pathology becomes especially apparent during CNS
infections, such as Japanese Encephalitis virus infection or
coronavirus-induced encephalitis, where IL-10 producing T cells
have been demonstrated to improve survival by ameliorating
immunopathology57,58. In the context of inﬂuenza infection,
however, the role of IL-10 still remains controversial as the
genetic background appears to have a dominant effect on disease
susceptibility59,60. More recently, Smith et al. demonstrated that
IL-10 can act directly on CD8+ T cells by increasing the antigenic
threshold for T cell activation and that this process was highly
dependent on the dose and timing of exposure17. Since the impact
of IL-10 is clearly determined by the timing and site of its pro-
duction, TIGIT modulation might be used as a surrogate to
generate a local immune suppressive environment at sites of
tissue inﬂammation. Our improved understanding of the local
effects of checkpoint inhibitors could thus feed into the devel-
opment of novel therapies for the treatment of inﬂammatory
diseases, where off target effects are encountered often and
interfere with treatment success. TIGIT stimulation might thus be
especially useful for prolonging graft survival or for managing
side effects of checkpoint inhibitor therapy in combination with
other checkpoint inhibitors. In conclusion, our results extend
previous knowledge of the importance of TIGIT in suppressing
immune cell activation and show a more specialized tissue-
protective role of TIGIT in response to viral challenges.
Methods
Mice. C57BL/6 (B6) mice were purchased from Janvier Labs. Congenic Ly5.161 and
Thy1.162, Foxp3-GFP.KI63 and Thy1.1-IL-10 reporter mice30, P1464, Smarta65, IL-
10[−/−66, and PKOB mice have been described previously and were all on C57BL/6
background. Mice were used between 8 and 16 weeks of age and were sex and age
matched within experiments. All animals were bred and housed in SPF and OHB
facilities at LASC Zürich, Switzerland. All experiments were performed in accor-
dance with institutional ethical policies and national regulations and have been
reviewed and approved by the Cantonal veterinary ofﬁce of Zurich.
Viruses and infections. The LCMV Clone 13 strain was propagated on
BHK21 cells. Brieﬂy, BHK21 cells were infected in suspension using a MOI of 0.1
(5 ml) for 1 h at RT in T175 tissue culture ﬂasks (TPP) in serum-free modiﬁed
Eagle medium (Gibco) on a plate shaker at minimum speed. After 1 h, 15 ml of
fresh modiﬁed Eagle medium (Gibco) supplemented with 5% FCS (Corning) and
1% L-glutamine (Gibco) were added and incubated at 37 °C and 10% CO2 for 48 or
72 h. Supernatants were frozen at −80 °C for long-term storage. Working stocks
were generated by diluting frozen stocks in PBS. Animals were infected i.v. with
either 2 × 106 FFU to induce chronic LCMV or with 1 × 105 FFU to induce an acute
LCMV infection. For IAV infection, mice were infected with 200 PFU of PR8
(H1N1, LD50= 1250 PFU) i.n. followed by antibody treatment on days 0, 2, 4 with
either 100 μg of mouse IgG1 or anti-TIGIT antibody (1G9). On day 8 p.i., mice
were injected i.v. with 200 μl of 0.5% Evans blue dye (EB, Sigma) in sterile 1× PBS
20 min before sacriﬁce. Animals were perfused with PBS, and the lung weight
measured. Lungs were then placed in 1 ml Formamide (Sigma) and incubated at
56 °C overnight. The amount of extracted Evans blue (EB) dye was measured by
photometry at 620 nm, and quantiﬁed against a standard curve using the following
formula: EB concentration (ng/ml) × volume of formamide (ml)/total lung weight
(g). Inﬂuenza virus was titrated by Plaque assay on MDCK cells.
Antibodies and MHC class I tetramers. The LCMV glycoprotein peptides gp33-
41 (gp33 peptide, KAVYNFATM) and gp61-80 (gp61, GLNGPDIYKGVYQFKS-
VEFD) were purchased from EMC microcolletions GmbH. Allophycocyanin
(APC)- conjugated peptide/MHC class I tetrameric complexes were generated as
previously described67. The following anti-mouse monoclonal antibodies were used
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from Biolegend: CD4 (RM4-5 or GK1.5), PD-1 (29 F.1A12), CD44 (IM7), CD8
(53-6.7), IFN-γ (XMG1.2), Lag-3 (C9B7W), TIGIT (1G9), TNF (MP6-XT22).
CD45.1 (A20) and CD90.1 (OX-7), CD49b (DX5), CD69 (H1.2F3), NKG2D
(CX5), CD11b (M1/70), MHCII (M5/114.15.2), Ly6C (HK1.4), Ly6G (1A8), NK1.1
(PK136), F4/80 (BM8). TCF-1/TCF7 (C63D9) was purchased from Cell Signaling
Technology. Tim-3 (215008) was purchased from R&D Systems. Granzyme B
(GB11) was purchased from Thermo Fisher. Dilution factors for the antibodies
used in this study can be found in Supplementary Table 1. The anti-TIGIT mAbs
for blockade (clone 1B4) and stimulation (clone 1G9) were described previously31.
Control animals were treated with mouse IgG1 (BioXCell).
Ex vivo stimulation and cytometric bead assay. Single-cell suspensions were
generated by mechanical disruption in RPMI 1640 medium (Gibco) supplemented
with 10% FCS (Corning), penicillin (100IU/ml, Gibco) and 1% L-glutamine
(Gibco). Red blood cells were removed by adding ACK lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH: 7.4) for 3 min. Splenocytes were
stimulated for 48 h in the presence of anti-CD3 (1 μg/ml) without additional anti-
TIGIT antibodies. Supernatants were stored at −20 °C for subsequent cytokine
analysis by cytometric bead assay (CBA). BioLegend’s LEGENDplex kit and the BD
CBA kit were used to detect soluble IL-10 protein according to the manufacturers’
instructions. The raw data were analyzed with LEGENDplex software (Biolegend)
or FCAP Array software (Soft Flow Inc.) to calculate unknown protein levels
against a known standard curve.
In vivo antibody treatment. Mice were injected i.p. with either 100 μg mouse IgG1
(BioXCell) or anti-TIGIT Abs (1G9 or 1B4 clone) as described previously31.
Injections were given on days 0, 2, 4, 10, 17, and 24 after infection if not stated
otherwise during chronic LCMV infection. The treatment regimen was shortened
accordingly during acute infections.
Adoptive cell transfers. Total CD4+ T cells or CD8+ T cells were pre-sorted from
spleens of naive Smarta mice and P14 TCR-α/β mice respectively using the
MojoSort mouse CD4 or CD8 T cell isolation kit (Biolegend) according to the
manufacturers’ instructions. In total, 1 × 104 cells per cell type were adoptively
transferred i.v. into C57BL/6 (B6) recipient mice. The following day, the recipient
mice were infected i.v. with 2 × 106 FFU LCMV Clone 13.
Focus-forming assay LCMV. Virus titers were determined as described pre-
viously68. Brieﬂy, MC57G cells were seeded at 5 × 105 cells/ml in 24 well plates in
modiﬁed Eagle medium supplemented with 5% FCS and 1% PSG. Organ samples
were homogenized by mechanical disruption using the TissueLyserII (Qiagen) and
centrifuged for 1 min at 4 °C at full speed. Samples were serially diluted onto the
MC57G cell layer and overlayed with 2% methylcellulose dissolved in 5% DMEM
medium (Gibco). The assay was incubated for 48 h at 37 °C in 5% CO2. After
2 days, cells were ﬁxed with 4% PFA for 30 min, followed by 20 min permeabili-
zation with 1% Triton X-100. The cell layer was washed twice with 1× PBS,
followed by 1 h incubation with 10% FCS in PBS at RT. The primary antibody (VL-
4 rat anti-LCMV mAb) was added 1:25 in PBS and incubated for 1 h at RT. Cells
were then washed twice with 1× PBS and incubated with the secondary antibody
peroxidase-conjugated goat anti-rat IgG (Jackson ImmunoResearch) 1:400 in 10%
FCS in PBS. OPD (Sigma-Aldrich) was added according to the manufacturer’s
instructions and incubated for at least 30 min at RT.
Plaque assay inﬂuenza A virus. To determine the amount of infectious IAV
particles, Madin–Darby Canine Kidney (MDCK) cells (ATCC CCL34) were
seeded into 12-well plates in Dulbecco’s Modiﬁed Eagle Medium (Life tech-
nologies) supplemented with 10% fetal bovine serum (Life technologies), 1% L-
glutamine (Life technologies), and 1% penicillin/streptomycin (Life technolo-
gies) at 37 °C in 5% CO2. At 100% cell conﬂuency, cells were washed once with
PBS supplemented with 20 μM Mg2+, 10 μM Ca2+, 0.3% (w/v) bovine serum
albumin (BSA), and 1% (v/v) penicillin–streptomycin (infection PBS) before
being infected with a series of tenfold dilutions of virus containing sample in
infection PBS. After 1 h incubation at 37 °C in 5% CO2, the inoculum was
removed, and the cells were covered with an agar overlay containing 0.7% (v/v)
Oxoid agar (Sigma-Aldrich) dissolved in Modiﬁed Eagle Medium (Life Tech-
nologies) supplemented with 10 μg/ml DEAE Dextran (Sigma-Aldrich), 0.1% (v/
v) sodium bicarbonat (Sigma-Aldrich) and 1 μg/ml tosylamide-2-phenylethyl-
chloromethyle-ketone (TPCK)-treated trypsin (Sigma-Aldrich). Cells were
incubated at 37 °C in 5% CO2 until plaques were visible. Then, cells were ﬁxed
with 3.7% PFA for 20 min at RT before staining with 0.5% (w/v) crystal violet
(Sigma-Aldrich) in ddH2O with 20% methanol for 10 min.
Flow cytometry. FACS stainings were performed on single-cell suspensions from
the spleen, liver, and lung. The spleen samples were prepared by mechanical dis-
ruption in RPMI 1640 medium supplemented with 10% FCS, penicillin (100IU/ml)
and 1% L-glutamine. Liver and lung were enzymatically digested for 30 min, and
immune cells isolated using a 30% Percoll (GE Healthcare) gradient. Red blood
cells were removed by adding ACK lysis buffer (155 mM NH4Cl, 10 mM KHCO3,
0.1 mM Na2EDTA, pH: 7.4) for 3 min. Cells were re-stimulated with either anti-
CD3 (1 μg/ml), gp33 peptide or gp61 peptide (EMC microcellections) and Bre-
feldin A solution (Biolegend) at 37 °C in 10% CO2 for 3–4 h before staining. For
surface stainings, antibodies were incubated for 20–30 min at RT in PBS. For
intracellular cytokine staining, spenocytes were permeabilized using the Cytoﬁx/
Cytoperm kit (BD Biosciences) for 5 min at RT, followed by antibody incubation
for 20–30 min at RT. For staining of transcription factors, cells were stained and
permeabilized with the Foxp3/Transcription factor staining buffer set
(eBioscience). The Zombie NIR ﬁxable dye was used to exclude dead cells and
debris. Data were acquired on a BD LSR Fortessa or BD FACS CantoII analyzer
(BD Bioscience) and analyzed using Flowjo software (TreeStar). Gating strategies
are shown in Supplementary Fig. 9.
Histopathology. Liver and lung lobes from IgG1 or anti-TIGIT Ab (1G9)-
treated and uninfected mice were ﬁxed in 4% paraformaldehyde and transferred
to 70% EtOH for storage before processing. The organs were trimmed, and
routinely parafﬁn wax embedded. Consecutive sections (3–5 µm) were prepared,
and routinely stained with hematoxylin-eosin (HE) or subjected to the Periodic
Acid Schiff (PAS) reaction for the demonstration of hepatocellular glycogen
accumulation. Livers were assessed for any histopathological changes including
leukocyte inﬁltration in a single blinded experimental setup, where the pathol-
ogist was unaware of the clinical status and treatment that the mice had received.
Histopathological changes were graded on the basis of the assessment schemes
published by Ishak et al.69 and Thoolen et al.70. The following histological
features were considered: leukocyte inﬁltration in portal areas, around central
vein and as random focal aggregates, and hepatocyte death (necrosis, apoptosis);
the distribution of changes was characterized as focal, multifocal, or diffuse
(grading from 0 to 3).
Analysis of serum liver AST and ALT. Serum AST and ALT were measured at
the Clinical Chemistry Department of the University Hospital, Zurich, Switzerland.
The catalytic concentration of both enzymes was measured at 37 °C with pyridoxal
phosphate activation on a Roche Cobas 8000 (c502) according to IFCC.
Statistical analysis. Statistical analyses were performed using Graphpad Prism.
Appropriate statistical tests were selected as indicated in the ﬁgure legends with
signiﬁcant differences marked on all ﬁgures. Differences between control and
treatment groups were determined using two-tailed Student's t test, including
Welch’s correction for unequal variants if necessary. To compare more than two
groups, we used one-way ANOVA with Tukey’s multiple comparisons test. His-
topathological data was evaluated using two-tailed Mann–Whitney test. Sig-
niﬁcance was deﬁned as p < 0.05 (*), p < 0.01 (**), p < 0.005 (***), or ns (not
signiﬁcant, p > 0.05).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon reasonable request. Raw data for all ﬁgures are provided as a Source
Data ﬁle.
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Supplementary Figure 1. Immune cell characterization during chronic LCMV infection +/- blocking anti-TIGIT (1B4) 
Ab treatment. C57BL/6 mice were infected with 2x106 FFU LCMV clone 13 i.v. and treated with 100µg control IgG1 or anti-
TIGIT Ab (1B4). (A) FACS quantification of PD-1 and Tim-3 expression on splenic CD8+ T cells throughout chronic LCMV 
infection is shown (n=23). (B) FACS quantification of PD-1 expression on splenic CD4+ T cells is shown, (n=12) (C) FACS 
quantification of CD4+ and CD8+ T cell counts in the spleen on day 30 p.i., (n=8). FACS quantification of (D) frequencies of 
myeloid cell populations and (E) absolute numbers of myeloid cell populations isolated from the spleen on day 5 p.i. (n=4). Each 
symbol in the scatter plot represents an individual mouse and bar graphs indicate the average value ± SEM. Statistical values. p < 
0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not significant, p > 0.05) determined by Student’s t test.  
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Supplementary Figure 2. NK cell phenotype during acute and chronic LCMV infection. C57BL/6 mice were infected with 
either 1x105 FFU LCMV clone 13 i.v. (grey) or 2x106 FFU LCMV clone 13 i.v. (red) and treated with 100µg control IgG1, 
agonistic anti-TIGIT Ab (1G9) and blocking anti-TIGIT Ab (1B4) on days 0, 2, 4 and 10 i.p. (A) TIGIT expression over the 
course of acute (dashed line) and chronic (solid line) LCMV infection measured on NK1.1+ cells by FACS (n=4-5). (B) Absolute 
numbers of NK1.1+ cells with and without blocking anti-TIGIT Ab (1B4) treatment on day 2 p.i. (n=4). (C) Absolute numbers of 
NK1.1+ cells with and without agonistic anti-TIGIT Ab (1G9) treatment on day 2 p.i. (n=4). (D) Phenotypic and functional 
analyses of NK1.1+ cells are shown on day 2 after chronic LCMV infection (n=4). (E) Phenotypic and functional analyses of 
NK1.1+ cells are shown on day 5 p.i after acute LCMV infection, (n=4). Each symbol in the scatter plot represents an individual 
mouse and bar graphs indicate the mean value ± SD. Pooled data from 1-2 independent experiments are shown. Statistical values. 
p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not significant, p > 0.05) determined by two tailed Mann-Whitney test. 
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Supplementary Figure 3. Myeloid cell phenotype during acute and chronic LCMV infection. Thy1.1 IL-10 reporter mice 
were infected with either 1x105 FFU LCMV clone 13 i.v. (grey) or 2x106 FFU LCMV clone 13 i.v. (red) and treated with 100µg 
control IgG1, anti-TIGIT Ab (1G9) or anti-TIGIT (1B4) on days 0, 2, 4 and 10 i.p. (A) IL-10 Thy1.1 expression on splenic 
myeloid cell population on day 5 after acute infection is shown, (n=3-4), pooled data from 2 independent experiments. (B) IL-10-
Thy1.1 expression on splenic myeloid cell population on day 14 after acute infection is shown, (n=3-4), pooled data from 2 
independent experiments. (C) IL-10-Thy1.1 expression on splenic myeloid cell population on day 5 after chronic infection is 
shown, (n=3). (D) IL-10-Thy1.1 expression on splenic myeloid cell population on day 30 after chronic infection is shown, (n=2-
5), pooled data from 1-2 independent experiments are shown. Each symbol in the scatter plot represents an individual mouse and 
bar graphs indicate the mean value ± SD. Statistical values. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not significant, p > 
0.05) determined by two tailed Mann-Whitney test.  
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Supplementary Figure 4. TIGIT stimulation alters the T cell phenotype and cytokine profile of T cells without affecting 
virus control. C57BL/6 mice or Thy1.1 IL-10 reporter mice were infected with 1x105 FFU LCMV clone 13 i.v. and treated with 
100µg control IgG1 or anti-TIGIT Ab (1G9) on days 0, 2 and 4 i.p. (A) Representative FACS plots of co-inhibitory receptor 
expression on splenic CD8+ T cells on day 5 p.i. are shown. (B) FACS quantification of co-inhibitory receptor expression and 
CD44 on splenic CD8+ T cells on day 5 p.i., (n=10-15). FACS quantification of intracellular TNF-α and IFN-γ produced by (C) 
anti CD3 re-stimulated splenic CD8+ T cells and (D) gp33 re-stimulated splenic CD8+ T cells, (n=10). (E) Virus titers in the 
spleen and liver on day 5 p.i. are shown, (n=9-12). (F) Virus kinetic in the spleen (n=3) is shown. (G) Virus kinetic in the liver 
(n=3) is shown. Each symbol in the scatter plot represents an individual mouse and bar graphs indicate the average value ± SD. 
Pooled data from 2-3 independent experiments are shown. Statistical values. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not 
significant, p > 0.05) determined by Student’s t test. 
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Supplementary Figure 5. TCF-1 expression on T cells during chronic LCMV infection. 10’000 P14 Ly5.1+ TCR transgenic 
CD8+ T cells specific for gp33 were transferred into C57BL/6 mice and infected with 2x106 PFU LCMV clone 13 i.v. and treated 
with 100µg control IgG1 or anti-TIGIT Ab (1B4) on days 0, 2, 4, 10 and 17 i.p. TCF-1 expression was measured on (A) P14 
Ly5.1+ TCR transgenic CD8+ T cells and (B) endogenous CD8+ T cells on indicated days post infection in the spleen (n=2-7). 
Each symbol in the scatter plot represents an individual mouse and bar graphs indicate the mean value ± SEM. Pooled data of 2-3 
independent experiments is shown. 
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Supplementary Figure 6. Effect of TIGIT agonism in WT and IL-10 KO mice. C57BL/6 mice and IL-10 KO mice were 
infected with 1x105 PFU LCMV clone 13 i.v. and treated with 100µg control IgG1 or anti-TIGIT Ab (1G9) on days 0, 2 and 4 
i.p. (A) Cytokine levels of C57BL/6 mice and IL-10 KO mice in ex vivo re-stimulated splenocyte supernatants on day 5 p.i. 
measured by flow cytometric bead assay (n=3). (B) The ratio of TNF-α to IL-10 protein in re-stimulated splenocyte supernatants 
on day 5 p.i. measured by flow cytometric bead assay (n=3). (C) The ratio of IFN-γ to IL-10 protein in re-stimulated splenocyte 
supernatants on day 5 p.i. measured by flow cytometric bead assay (n=3). Serum levels of (D) aspartate-aminotransferase (AST) 
and (E) alanine-aminotransferase (ALT) measured on day 5 p.i. are shown (n=3-9). (F)-Virus loads in WT and IL-10 KO mice 
on day 5 p.i. are shown (n=3). (G) Representative focus forming assay plate of WT and iL-10 KO mice on day 5 p.i. is shown. 
Each symbol in the scatter plot represents an individual mouse and bar graphs indicate the mean value ± SD. Pooled data of 2 
independent experiments is shown. Statistical values. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not significant, p > 0.05) 
determined by one-way ANOVA (Holm-Sidak post test) if more than two groups were compared and one tailed Mann Whitney 
test if two groups were compared. 	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Supplementary Figure 7. Effect of blocking anti-TIGIT (1B4) Ab treatment in various infection models. C57BL/6 mice 
were infected with either 1x105 FFU LCMV clone 13 i.v., 2x106 FFU LCMV clone 13 i.v. or 200 PFU IAV PR8 i.n. and treated 
with 100µg control IgG1 or anti-TIGIT (1B4) on days 0, 2, 4, 10, 17, 24 i.p. (chronic dose, light red) or on days 0, 2, 4 (acute 
dose, dark red). (A) Weight loss curve of chronically infected mice treated with control IgG1 and anti-TIGIT (1B4) Ab is shown 
(n=10). (B) Serum levels of aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) measured on day 30 p.i. are 
shown (n=11-13). Serum levels of (C) aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) measured on day 
10 p.i. are shown (n=8). (D) Cytokine levels in whole lung homogenates measured on day 8 p.i. IAV PR8 i.n. measured by flow 
cytometric bead assay are shown (n=4-15). (E) Histological features and IAV antigen expression in the lungs of or anti-TIGIT 
(1B4) Ab treated animals. (I) Consolidated area with increased interstitial cellularity and bronchiole (*) with degenerate 
epithelial cells (arrowhead) and some debris in the lumen. Artery (A) with activated endothelial cells (bulging into the vessel 
lumen). (II) Consecutive section showing IAV antigen expression in respiratory epithelial cells (arrows) and luminal cell debris 
in bronchiole (*), and in type I pneumocytes (arrowheads) and type II pneumocytes/alveolar macrophages (short arrows). (a) (HE 
stain), (b) (immunohistology for IAV antigen), Bars = 20 µm. (F) Virus load in lungs measured on day 8 p.i. by plaque assay 
(n=4). Each symbol in the scatter plot represents an individual mouse and bar graphs indicate the mean value ± SD. Statistical 
values. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***) ns (not significant, p > 0.05) determined by Student’s t test. 
Supplementary Figure 8. Lung phenotype and virus quantification after influenza infection. C57BL/6 mice were infected 
i.n. with 200 PFU influenza A virus PR8 and treated with 100µg control IgG1 or anti-TIGIT Ab (1G9) on days 0, 2 and 4 i.p. 
Virus burden was measured by plaque assay on indicated days post infection (A) lung tissue and (B) bronchoalveolar lavage 
(n=4-5). (C) Histological features and (D) IAV antigen expression in the lungs on day 8 p.i.: Figure panel of IgG1 treated mice 
(C, I) Consolidated area with increased interstitial cellularity and bronchioles (*) with individual degenerate epithelial cells 
(arrowheads) and some debris in the lumen. Artery (A) with activated endothelial cells (bulging into the vessel lumen). (D, I) 
Consecutive section showing IAV antigen expression in respiratory epithelial cells (arrows) and luminal cell debris in 
bronchioles (*), and in type I pneumocytes (arrowheads) and type II pneumocytes/alveolar macrophages (short arrows). (C, III) 
Larger vein with activated endothelial cells (arrowhead) and rolling and emigrating leukocytes (arrows). Inset: Mild arteritis with 
neutrophils in the media (arrowhead) and as aggregates (arrows) in the adjacent tissue: Mice treated with agonistic anti-TIGIT 
(1G9) Ab (C, II): Moderately consolidated area with increased cellularity and bronchiole (*) with focal area of epithelial cell loss 
(arrow) and degenerate epithelial cells (arrowhead). (D, II) Section showing IAV antigen expression in respiratory epithelial cells 
(arrow) and luminal cell debris in a bronchiole (*), and in type I pneumocytes (arrowhead) and type II pneumocytes/alveolar 
macrophages (short arrows). (C, IV) Larger vein with activated endothelial cells (arrowhead) and mild perivascular mononuclear 
(macrophages and lymphocytes) infiltrates (arrows). (C) (HE staining), (D) (immunohistology for IAV antigen). Bars = 20 µm 
(C-D, I, II) and 10 µm (C, III, IV). (E) Pathology score of IgG1, agonistic anti-TIGIT (1G9) Ab or blocking anti-TIGIT (1B4) 
Ab treated lungs, single-blinded analysis. The degree of neutrophil infiltration and vasculitis was assessed by light microscopy. 
Box plot and whiskers displaying the minimum and maximum of all data points. Statistical values. p < 0.05 (*), p < 0.01 (**), p 
< 0.005 (***) ns (not significant, p > 0.05) determined by two tailed Mann-Whitney test (A-B) and Kruskal-Wallis test (E).  
 
 
Supplementary Figure 9. Gating strategies. T cell compartment and myeloid immune cells. 
 
 
Ab Clone Cat. number Dilution Supplier 
CD4 RM4-5 100552 1:200 Biolegend 
CD4 GK1.5 100453 1:200 Biolegend 
PD-1 29F.1A12 135220 1:200 Biolegend 
CD44 IM7 103026 1:400 Biolegend 
CD8 53-6.7 100710 1:500 Biolegend 
IFN-γ XMG1.2 505808 1:300 Biolegend 
Lag-3 C9B7W 125221 1:200 Biolegend 
TIGIT 1G9 142110 1:50 Biolegend 
TNF-α MP6-XT22 506324 1:500 Biolegend 
CD45.1 A20 110706 1:200 Biolegend 
CD90.1 OX-7 202529/ 
202537 
1:400 Biolegend 
Granzyme B GB11 MHGB05 1:50 Thermo Fisher 
CD49b DX5 108920 1:200 Biolegend 
CD69 H1.2F3 104514 1:200 Biolegend 
NKG2D CX5 130208 1:100 Biolegend 
CD11b M1/70 101212 1.400 Biolegend 
MHCII M5/114.15.2 107604 1:800 Biolegend 
Ly6C HK1.4 128037 1:400 Biolegend 
Ly6G 1A8 127645 1:400 Biolegend 
NK1.1 PK136 108738 1:100 Biolegend 
F4/80 BM8 123114 1:400 Biolegend 
TCF1/TCF7 C63D9 2203S 1:100 Cell Signaling Technology 
Tim-3 215008 FAB1529P 1:200 R&D Systems 
 
Supplementary Table 1: FACS antibodies. Information about the antibodies used for FACS stainings is summarized. 
 
